Stephen S. Tang Named NOWDiagnostics Board Chairman

NOWDiagnostics (NOWDx) has chosen Stephen S. Tang, Ph.D., to chair its Board of Directors.
 
Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies Inc., a developer of rapid at-home tests for HIV and COVID-19, for 10 years as president and CEO, board chairman, and compensation committee chairman. During his tenure as president and CEO, OraSure launched more U.S. Food and Drug Administration (FDA)-cleared products, expanded its sales, and developed and acquired more innovative products and services in its history.

“We are pleased to welcome Stephen as chairman of the board, and particularly fortunate for his expert understanding of the impact that at-home diagnostics can have in early detection of diseases. His deep knowledge in the diagnostics space and his impactful leadership at OraSure will be invaluable as we await FDA authorization for our first at-home test for syphilis and set up our entire product portfolio for commercial launch,” NOWDiagnostics CEO Rob Weigle said. “In addition, his broad leadership experience in research and life sciences roles will help to guide our strategic vision of becoming the go-to choice for at-home and point-of-care diagnostics.”

Before joining OraSure, Dr. Tang was president and CEO of the University City Science Center in Philadelphia, the mid-Atlantic region’s innovation hub for life science companies. He also led Olympus America’s Life Sciences Group, which included laboratory diagnostic, microscope, and translational research instruments. He earned his bachelor of science degree in chemistry from the College of William & Mary, masters of science degree and Ph.D. in chemical engineering from Lehigh University, and an MBA for Executives from The Wharton School of Business at the University of Pennsylvania. In 2016, he was awarded a Doctor of Humane Letters (honoris causa) from Thomas Jefferson University (formerly Philadelphia University) and the Wagner Free Institute of Science.
 
“I am delighted and enthusiastic about joining the NOWDx team as their chairman of the board,” Dr. Tang stated. “For many years, the medical diagnostic industry has sought to bring in-home tests from the lab to regulatory approval and widespread consumer use. More than ever, NOWDx brings us all closer to fulfilling that vision for better, more accessible healthcare for everyone with its in-home test, with in-home results in minutes platform. I am honored to join an engaged Board of Directors to assist an  experienced team led by CEO Rob Weigle.” 

Dr. Tang currently serves on the Boards of Directors of several nonprofit organizations, including the William & Mary Foundation, Population Services International, Lehigh University, Team Pennsylvania Foundation, and Life Sciences Pennsylvania. 
 
“As a diagnostic fund, we at DigitalDx Ventures are incredibly excited to welcome Steve Tang to the NOWDx Board of Directors as its board chair,” DigitalDx Founder/Managing Partner Michele Colucci said. “Very few professionals have the depth of experience in the diagnostic industry as Steve does, much less his level of expertise in the boardroom. His steady, supportive hand, collaborative approach, and revenue focus are exemplary and exactly what is needed to harness the talent in the C-suite and complement the existing composition of the board. Boards are often like a puzzle, and in this context we’d say he’s the perfect fit.”
 
“We are very much looking forward to the leadership and strategic direction that Stephen Tang will provide NOWDx,” stated Jeremy Wilson, co-founder of NOWDx and co-managing partner of private equity firm NewRoad Capital Partners. “With his heavy-hitting expertise, he will position the company very well for future growth, while creating impact and innovation in the diagnostics industry.”
 
NOWDx develops and manufactures “Touch to Test” over-the-counter and point-of-care diagnostic tests that yield results in minutes. Its patented approach allows for virtually any immunological assay to be accurately performed onsite in one step using a tiny amount of capillary blood or, in some cases, saliva. The company is based in Springdale, Ark.